Immunoprecise Stock Price, News & Analysis

ImmunoPrecise Antibodies (NASDAQ: IPA) has validated its AI-powered epitope mapping platform, LENSai, demonstrating its ability to accurately predict antibody binding sites on completely new, unseen therapeutic targets. The platform successfully mapped 17 previously unseen antibody-protein complexes with accuracy levels comparable to its performance on training data.

Powered by IPA's patented HYFT® technology, LENSai can predict binding sites in hours using only digital sequences, significantly reducing the time and cost compared to traditional lab-based methods that take months. The platform achieved consistent AUC (Area Under the Curve) scores across both familiar and new molecular complexes, proving its ability to generalize across diverse biological structures.

ImmunoPrecise (NASDAQ: IPA) has achieved a significant milestone in developing a universal dengue vaccine using its LENSai™ Platform and HYFT® Technology. The company has validated that their newly discovered vaccine target is conserved across all four dengue virus types, demonstrating safety, immune activation, and structural stability.

The breakthrough involves a unique target site that triggers both B-cell and T-cell responses while maintaining strong predicted binding to multiple human immune system markers. Key technical findings include complete immune response testing, comprehensive safety verification against human proteins, and confirmation of structural stability. The balanced immune response profile suggests reduced risk of dangerous immune overreactions or antibody-dependent enhancement (ADE).

This validation follows the company's June 5th announcement and strengthens the candidate's translational potential as it moves toward preclinical evaluation.

ImmunoPrecise Antibodies (NASDAQ: IPA) has achieved a significant breakthrough in AI-driven drug discovery, with their AI-designed GLP-1 receptor agonist peptides showing superior or comparable performance to Semaglutide in receptor activation studies. The research, validated by independent third-party testing, demonstrates the effectiveness of IPA's LENSai platform and HYFT technology in designing peptide sequences. Two lead candidates outperformed or matched Semaglutide in controlled assays. The company is pursuing both injectable delivery studies and non-invasive delivery strategies for these candidates. This success validates IPA's AI-driven approach, which can be applied to other therapeutic targets across various disease areas. The technology has already shown success in vaccine development, particularly with dengue virus candidates.

ImmunoPrecise Antibodies (NASDAQ:IPA) has achieved a significant breakthrough in dengue vaccine development using its AI-driven LENSai platform powered by HYFT technology. The company has discovered a conserved epitope present across all four dengue virus serotypes, potentially enabling the development of a universal dengue vaccine. This discovery was made entirely through in silico methods, using over 20 million proprietary Structural HYFTs (S-HYFTs) to validate the findings. The platform's success demonstrates its ability to identify viral signatures that remain constant despite mutations, marking a significant advancement in computational vaccinology. IPA plans to extend this AI-driven vaccine design platform to other diseases including HIV, Norovirus, RSV, and potentially certain types of cancer.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutics company, has announced its engagement with CORE IR, a strategic investor and public relations firm. The partnership aims to enhance IPA's investor relations and communications initiatives. CORE IR will provide comprehensive services including strategic messaging, investor outreach, and communication program support. Dr. Jennifer Bath, CEO of IPA, emphasized this collaboration as a crucial step in improving communication with the investment community and increasing market visibility as the company executes its growth strategy. Scott Gordon, Co-Founder and President of CORE IR, expressed enthusiasm about working with IPA, recognizing the company's position as a pioneer in antibody discovery and development.

ImmunoPrecise Antibodies (NASDAQ: IPA), an AI-driven biotherapeutics company, announced that CEO Dr. Jennifer Bath will present at Maxim Group's 2025 Virtual Tech Conference on Tuesday, June 3rd at 11:00 AM EDT. The conference, running from June 3rd to 5th, will focus on technological disruption across various industries, with particular emphasis on Quantum Computing and AI applications.

The virtual event, hosted on the M-Vest Platform, will feature discussions between Maxim Senior Analysts and company executives about how emerging growth companies are leveraging advanced technologies for future positioning. The conference will explore innovation impacts across healthcare, drones, consumer IoT, business solutions, and gaming & entertainment sectors.

ImmunoPrecise Antibodies (NASDAQ:IPA) has announced breakthrough results for its LENSai™ AI platform's epitope mapping capabilities. The platform matched the accuracy of gold-standard x-ray crystallography in antibody-antigen analysis, but delivers results in hours instead of months. In benchmarking tests across five antibody-antigen pairs, LENSai achieved predictive scores (AUC 0.79-0.89) comparable to or better than traditional wet-lab methods.

The platform's ability to provide accurate epitope mapping insights using only sequence data represents a significant advancement in computational biology and antibody discovery, where industry failure rates exceed 95%. This development aligns with FDA's move to phase out animal testing requirements for biologics and offers a more ethical, scalable approach to biotherapeutic discovery.

ImmunoPrecise Antibodies (NASDAQ: IPA) has expressed strong support for the FDA's decision to phase out animal testing requirements for monoclonal antibodies and pharmaceutical products. The company's AI platform, LENSai™, aligns with this regulatory shift by providing validated AI-driven methodologies that support New Approach Methodologies (NAMs).

The platform offers three key capabilities:

• Safety and Toxicity Prediction through AI analytics mapping drug interactions across the human proteome
• Immunogenicity Screening to identify immune response risks and optimize patient strategies
• Knowledge Graphs for Drug Efficacy that integrate biological data for precise drug interaction predictions

According to CEO Dr. Jennifer Bath, this transition aims to streamline preclinical workflows, reduce development costs, and maintain higher ethical standards while ensuring regulatory compliance.

ImmunoPrecise Antibodies (IPA) reported Q3 FY25 financial results, securing an $8-10M strategic partnership for co-developing Antibody-Drug Conjugates and bispecific antibodies. The company expanded AI infrastructure through collaborations with Vultr and GPU technology providers.

Key financial highlights include:

• Revenue remained stable at $6.2M
• BioStrand showed 131.8% YoY revenue growth with 97% gross margin
• Net loss of $21.5M ($0.66 per share) vs $2.7M loss in FY24 Q3
• Cash position of $12.9M as of January 31, 2025

Notable developments include headquarters relocation to Austin, Texas, completion of an $8.8M ATM equity raise, and full conversion of Yorkville debenture. The company recorded a $21.2M impairment charge related to BioStrand's intangible assets.